PLAT and ischemic stroke: Notably, tissue-type plasminogen activator (tPA) is widely recognized as the primary thrombolytic drug for the clinical treatment of ischemic stroke due to its neuroprotective effects, which involve the modulation of FUNDC1-mediated mitophagy [188].